Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage IV prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 103 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR105505, NCI-2015-00725, 56021927PCR3001, NCT02257736
Calcitriol in Combination with Ketoconazole and Therapeutic Hydrocortisone in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 68905, NCI-2011-00129, RPCI-I-68905, NCT00536991
Zoptarelin Doxorubicin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 4P-09-9, NCI-2009-01418, NCT01240629
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Ipilimumab and Abiraterone Acetate in Treating Patients with Previously Untreated Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-120, NCI-2012-01878, c12-097, NCT01688492
Alisertib, Abiraterone Acetate, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13P.128, NCI-2013-00895, 2013-02, NCT01848067
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB13-0979, NCI-2013-02151, CDMRP-PC121149, NCT02012296
Hormone Therapy and Ipilimumab in Treating Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC0253, NCI-2009-01214, NCT00170157
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: J07122, NCI-2010-02020, JHOC-J07122, JHOC-NA_00010227, NCT00670046
Phenelzine Sulfate and Docetaxel in Treating Patients with Prostate Cancer with Progressive Disease after First-Line Therapy with Docetaxel
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00005688, NCI-2010-02037, 5688, MR00045508, OHSU-5688, SOL-09105-LM, NCT01253642
Neoadjuvant Axitinib in Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2011-02749, NCT01409200
Ipilimumab in Combination with Androgen Suppression Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5254, NCI-2011-03556, 08-004, BMS#CA184059, CA184059, MR00039104, OHSU-5254, NCT01498978
Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7639, NCI-2011-03745, 0801, NCT01508234, NCT01503229
Abiraterone Acetate in Treating Patients With Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 11-0709, NCI-2012-00116, NCT01543776
Trebananib and Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12C0079, NCI-2013-01535, 00003846, 120079, 751173, P11890, 9068, NCT01553188
Sipuleucel-T with or without Indoximod in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011LS109, NCI-2012-00923, 1202M10704, NCT01560923
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0109, NCI-2012-01149, CDR0000730114, UCCRC-IL057, 9012, IL057, NCT01576172
Metformin Hydrochloride in Treating Patients with Advanced or Metastatic Prostate Cancer Undergoing Castration
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTRC 10-21, NCI-2012-01607, HSC20110273, HSC20110273H, IDD# 10-21, NCT01620593
Start Over